Clinical trials: Depressive Disorders
Depression
Evaluating the Effectiveness of Escitalopram to Prevent Depression in Head and Neck Cancer Patients Receiving Treatment
This study will evaluate the effectiveness of escitalopram to prevent depression in head and neck cancer patients receiving treatment.
- Trial name
- PROTECT (NCT00536172)
- Testing
- Escitalopram
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- University of Nebraska
Major Depressive Disorder (MDD)
A Study of Flexible or Fixed Dose LY2216684 as Adjunctive Treatment for Participants With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment
The purpose of this study is to assess if LY2216684 (flexible dose of 12 to 18 milligrams [mg] or fixed dose of 6 mg once daily) is superior to placebo once daily in the adjunctive treatment of participants with Major Depressive…
- Trial name
- NCT01187407
- Testing
- LY2216684, SSRI
- Where
- 54 sites in United States, Croatia and 5 more
- Volunteers
- 1,480 people
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder
Ketamine Treatment Effects on Synaptic Plasticity in Depression
Depression is the leading cause of disability globally (1, 2). One-third to one-half of patients suffering from major depressive disorder (MDD) do not achieve remission even after multiple antidepressant trials (3).
- Trial name
- NCT04091971
- Testing
- Ketamine
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- New York State Psychiatric Institute
Major Depressive Disorder
Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder
The purpose of this study is to evaluate the efficacy, safety, and tolerability of Levomilnacipran ER fixed doses versus placebo in the treatment of outpatients with major depressive disorder.
- Trial name
- NCT00969709
- Testing
- Levomilnacipran ER
- Where
- 38 sites in United States
- Volunteers
- 724 people
- Sponsor
- Forest Laboratories
Depressive Disorder
Safety and Efficacy Study in Patients With Major Depressive Disorder
The purpose of this study is to test if GSK163090 can reduce the symptoms of depression. The safety and how well the body can handle the drug will also be investigated.
- Trial name
- NCT00896363
- Testing
- GSK163090 1 mg, GSK163090 3 mg
- Where
- 15 sites in Russia
- Volunteers
- 99 people
- Sponsor
- GlaxoSmithKline
Bipolar Disorder I or II
Tranylcypromine Treatment of Bipolar Depression
This study seeks to investigate whether tranylcypromine (Parnate®) might be an effective treatment of bipolar depression. New treatments are needed, as there is little evidence that standard antidepressants are effective in…
- Trial name
- NCT01430455
- Testing
- Tranylcypromine
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- New York State Psychiatric Institute
Depression
Pre-Treatment Positron Emission Topography Scanning for Increasing Success in Antidepressant Treatment
This study will use pre-treatment positron emission topography and functional magnetic resonance imaging scans of the brain to predict the most effective antidepressant treatment for people with major depressive disorder.
- Trial name
- NCT00456014
- Testing
- Escitalopram, Desipramine
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- New York State Psychiatric Institute
Major Depressive Disorder
Therapist-Guided Smartphone-Delivered CBT for MDD
We are testing a smartphone app that provides therapy for depression. Participants will also receive short weekly virtual appointments with a therapist.
- Trial name
- NCT05386329
- Testing
- Mindset: Therapist-guided smartphone-delivered CBT
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Massachusetts General Hospital
Military Personnel, Family Members
Telephone Support During Overseas Deployment for Military Spouses
Deployment impacts both service member and family, and the cost can be high. Spouses' reactions to deployment may include emotional distress, loneliness, anticipatory fear or grief, somatic complaints, and depression.
- Conditions
- Military Personnel, Family Members, Resilience, Psychological, Deployment
- Trial name
- NCT01828983
- Testing
- Telephone support groups, Education webinars
- Where
- United States
- Volunteers
- 161 people, healthy volunteers welcome
- Sponsor
- Memphis VA Medical Center
Major Depressive Disorder, Depression
A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder
The purpose of this study is to determine if TC-5214 or placebo (a tablet that looks like medicine tablet or capsule, but contains no active medicine) is safe and effective when taken together with another antidepressant.
- Trial name
- NCT01180400
- Testing
- TC-5214
- Where
- 66 sites in Czechia, Estonia and 8 more
- Volunteers
- 295 people
- Sponsor
- AstraZeneca
Mental Health Issue, Breast Cancer
Evaluating Digital Micro-Interventions to Reduce Distress and Increase Wellbeing in Breast Cancer Survivors
Digital mental and behavioral health interventions have potential to significantly improve accessibility for the large number of breast cancer survivors who need treatments.
- Trial name
- NCT07160439
- Testing
- Digital Micro-Interventions
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- University of Virginia
Depression
Demonstration Study of the Effect of the Transcranial Direct Current Stimulation (tDCS) on Depressed Patients
Purpose of research: It aims to demonstrate the effectiveness of transcranial direct current stimulation (tDCS) in the clinical domain for patients with depression and to optimize home-based e-medication technology.
- Trial name
- NCT05539131
- Testing
- transcranial direct current stimulation (tDCS)
- Where
- 5 sites in South Korea
- Volunteers
- 198 people
- Sponsor
- Yonsei University
Major Depressive Disorder, Suicidal Ideation
Paliperidone and Lithium in the Treatment of Suicidality - Treatment Indication and Epigenetic Regulation
The study aims to use a combined clinical and translational approach to identify an efficient pharmacotherapy for the acute management of suicidality and the epigenetic regulation associated with the treatment.The primary…
- Trial name
- AFSP (NCT01134731)
- Testing
- paliperidone, lithium
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- University of Alabama at Birmingham
Cardiac Surgery, Older Adults
Behavioral Activation and Medication Optimization In Older Adults Undergoing Cardiac Procedures
This Hybrid 1 Study will test the effectiveness of a bundled intervention comprised of behavioral activation and medication optimization in reducing symptoms of depression and anxiety in older adults undergoing cardiac surgery…
- Conditions
- Cardiac Surgery, Older Adults, Depression, Anxiety
- Trial name
- NCT05575128
- Testing
- Behavioral activation, Medication optimzation, Care as usual
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- Washington University School of Medicine
Major Depressive Disorder (MDD)
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)
This will be a multicenter, randomized, double-blind study designed to assess the efficacy, safety and tolerability of an oral Aripiprazole/Escitalopram combination therapy in participants with MDD who have demonstrated an…
- Trial name
- NCT01111552
- Testing
- Escitalopram, Aripiprazole
- Where
- 60 sites in United States, Australia and 5 more
- Volunteers
- 237 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Depressive Disorder, Major
A Study to Test the Effect of Different Doses of BI 1358894 and Quetiapine in People With Depression
This study is open to adults with depression (major depressive disorder) for whom standard treatment with antidepressants alone does not work sufficiently.
- Trial name
- NCT04521478
- Testing
- BI 1358894, Quetiapine
- Where
- 120 sites in United States, Argentina and 12 more
- Volunteers
- 389 people
- Sponsor
- Boehringer Ingelheim
Major Depressive Disorder
A Study to Assess the Effect and Safety of AZD6765 in Patients With Major Depressive Disorder
The purpose of this study is to assess the effect and safety of AZD6765 in patients with major depressive disorder who exhibit inadequate response to antidepressants.
- Trial name
- NCT01482221
- Testing
- AZD6765 iv
- Where
- 44 sites in United States, Chile and 2 more
- Volunteers
- 542 people
- Sponsor
- AstraZeneca
Major Depressive Disorder
Comparison of Behavioral Activation and Antidepressant Medication in the Treatment of Adolescents With Depression
This study focuses on treating adolescents with depression. The study has two main purposes. The first is to compare a new form of therapy for depression called Behavioral Activation (BA) to the antidepressant medication…
- Trial name
- NCT01740726
- Testing
- Behavioral Activation, Fluoxetine
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Emory University
Major Depressive Disorder
Connectivity Affecting the Antidepressant REsponse Study
It can be difficult to achieve remission in individuals with late-life depression (LLD) and they often require aggressive treatment. This challenge is in part due to age-related vascular changes that are common in LLD.
- Trial name
- CAARE (NCT02332291)
- Testing
- Escitalopram, Bupropion XL
- Where
- United States
- Volunteers
- 95 people
- Sponsor
- Vanderbilt University Medical Center
Major Depressive Disorder
Efficacy and Safety of Cranial Electrical Stimulation (CES) for Major Depressive Disorder (MDD)
The purpose of this study is to see if using Cranial Electrical Stimulation (CES) helps improve symptoms of major depressive disorder (MDD).
- Trial name
- NCT01325532
- Testing
- Active CES
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Massachusetts General Hospital